Tag: NVL-520
-
GSK Plans First-Line Jideytro Filing After 94% Response Rate
GSK plans to seek first-line FDA approval for Jideytro after the ROS1 inhibitor achieved a 94% response rate in 94 TKI-naïve patients in the ARROS-1 study.
-
How Jideytro Blocks ROS1 Fusion Signaling in Lung Cancer
Jideytro is a brain-penetrant, TRK-sparing macrocyclic inhibitor designed to block ROS1 fusion signaling and resistant variants such as G2032R.